All Updates

All Updates

icon
Filter
Partnerships
Janssen Pharmaceuticals partnered with Predicine to develop urine-based test as CDx tool to focusing on bladder cancer
Precision Medicine
Jan 8, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Jan 8, 2024

Janssen Pharmaceuticals partnered with Predicine to develop urine-based test as CDx tool to focusing on bladder cancer

Partnerships

  • CDx tools provider Janssen Pharmaceuticals has entered a partnership with Predicine to develop a urine-based test as a CDx tool to identify bladder cancer patients who may find targeted therapies effective. Financial terms of the partnership were not disclosed.

  • California-based Predicine’s next-generation sequencing-based (NGS) test is used to detect cell-free DNA alterations to cancer-relevant genes, including single nucleotide variants, insertions, deletions, fusions, and copy number variations.

  • In August 2022, Predicine also secured a CE-IVD mark for PredicineCare as a blood and urine cfDNA test that is capable of targeting 152 genes which are actionable and linked with available therapies or those in clinical trials. In addition, in August 2022, the company received the US FDA breakthrough device designation for the PredicineCare test. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.